# reload+after+2024-01-22 19:46:44.588049
address1§77 Sir John Rogerson’s Quay
address2§Block C Grand Canal Docklands
city§Dublin
zip§2
country§Ireland
phone§353 1 236 2500
fax§353 1 902 3510
website§https://www.prothena.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease and other related synucleinopathies; NNC6019 that completed Phase I clinical trial for the treatment of ATTR amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease, as well as TDP-43 and PRX019 for the treatment of Alzheimer's disease and other neurodegenerative diseases. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
fullTimeEmployees§127
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Gene G. Kinney Ph.D.', 'age': 54, 'title': 'President, CEO & Director', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 1030130, 'exercisedValue': 2913246, 'unexercisedValue': 66794400}, {'maxAge': 1, 'name': 'Mr. Tran B. Nguyen M.B.A.', 'age': 49, 'title': 'CFO & Chief Strategy Officer', 'yearBorn': 1974, 'fiscalYear': 2022, 'totalPay': 762855, 'exercisedValue': 3844286, 'unexercisedValue': 30658202}, {'maxAge': 1, 'name': 'Mr. Brandon S. Smith', 'age': 48, 'title': 'Chief Operating Officer', 'yearBorn': 1975, 'fiscalYear': 2022, 'totalPay': 756414, 'exercisedValue': 0, 'unexercisedValue': 9072775}, {'maxAge': 1, 'name': 'Ms. Carol D. Karp', 'age': 70, 'title': 'Chief Regulatory Officer', 'yearBorn': 1953, 'fiscalYear': 2022, 'totalPay': 697512, 'exercisedValue': 0, 'unexercisedValue': 14620238}, {'maxAge': 1, 'name': 'Dr. Hideki  Garren M.D., Ph.D.', 'age': 58, 'title': 'Chief Medical Officer', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 809586, 'exercisedValue': 526095, 'unexercisedValue': 2692468}, {'maxAge': 1, 'name': 'Ms. Karin L. Walker CPA', 'age': 60, 'title': 'Chief Accounting Officer & Controller', 'yearBorn': 1963, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Wagner M. Zago', 'age': 50, 'title': 'Chief Scientific Officer', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 478789, 'exercisedValue': 0, 'unexercisedValue': 58739}, {'maxAge': 1, 'name': 'Ms. Jennifer  Zibuda', 'title': 'Director of Investor Relations & Communication', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Michael J. Malecek', 'age': 57, 'title': 'Chief Legal Officer & Company Secretary', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 588250, 'exercisedValue': 0, 'unexercisedValue': 154061}]
auditRisk§8
boardRisk§3
compensationRisk§6
shareHolderRightsRisk§3
overallRisk§4
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.286
priceToSalesTrailing12Months§15.477923
currency§USD
dateShortInterest§1702598400
forwardEps§-4.45
pegRatio§24.75
exchange§NMS
quoteType§EQUITY
shortName§Prothena Corporation plc
longName§Prothena Corporation plc
firstTradeDateEpochUtc§1355841000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§2c74736f-3970-3936-8149-66656e11ad39
gmtOffSetMilliseconds§-18000000
targetHighPrice§129.0
targetLowPrice§43.0
targetMeanPrice§83.63
targetMedianPrice§81.0
recommendationMean§1.8
recommendationKey§buy
numberOfAnalystOpinions§11
quickRatio§12.667
grossMargins§-0.36646998
ebitdaMargins§-0.79265
trailingPegRatio§None
